Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy

Psycho-Oncology

Volumn 22, Issue 10, 2013, Pages 2169-2176

  Chipperfield, Kelly ^a   Fletcher, Jane ^a,b   Millar, Jeremy ^a,c   Brooker, Joanne ^a,b   Smith, Robin ^c   Frydenberg, Mark ^a,d   Burney, Sue ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b CABRINI INSTITUTE   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d MONASH MEDICAL CENTRE   (Australia)

Author keywords

anxiety; depression; Oncology; physical activity; prostate cancer; quality of life

Indexed keywords

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANXIETY; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; COMORBIDITY; DEPRESSION; FUNCTIONAL ASSESSMENT; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PROSTATE CANCER; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT DURATION; TREATMENT RESPONSE; AGE; AUSTRALIA; BRACHYTHERAPY; MIDDLE AGED; MOTOR ACTIVITY; PROSTATECTOMY; PROSTATIC NEOPLASMS; PSYCHOLOGY; RADIOTHERAPY; RISK FACTOR; STATISTICAL MODEL;

ANTIANDROGEN;

AGE FACTORS; AGED; ANDROGEN ANTAGONISTS; ANXIETY; AUSTRALIA; BRACHYTHERAPY; COMORBIDITY; DEPRESSION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RADIOTHERAPY; RISK FACTORS;

EID: 84885300584     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.3269     Document Type: Article

References (70)

1. Prostate Cancer Foundation of Australia. Prostate Cancer Statistics. 2012 28.3.2012; Available from: http://www.prostate.org.au/articleLive/pages/ Prostate-Cancer-Statistics.html.
2. Kirby RS, Patel MI,. Fast Facts: Prostate Cancer. Health Press Limited: Oxford, UK, 2008.
3. Galvao DA, Taaffe DR, Spry N, Newton RU,. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer. Prostate Cancer Prostatic Dis 2007; 10: 340-346.
4. Shahinian VB, Kuo Y-F, Freeman JL, Orihuela E, Goodwin JS,. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005; 103: 1615-1624.
5. Sharifi N, Gulley JL, Dahut WL,. Androgen deprivation therapy for prostate cancer. J Am Med Assoc 2005; 294: 238-244.
6. Scherr D, Swindle PW, and, Scardino PT,. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 2003; 61: 14-24.
7. Sadetsky N, Greene K, Cooperberg MR, Hubbard A, Carroll, PR, and, Satariano W,. Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. Cancer 2011; 117: 4406-4413.
8. Keating NL, O'Malley J, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-4456.
9. Taylor LG, Canfield SE, Du XL,. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009; 115: 2388-2399.
10. Lage MJ, Barber BL, Markus RA,. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology 2007; 70: 1104-1108.
11. Freedland SJ, Eastham J, Shore N,. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 2009; 12: 333-338.
12. Fowler FJ, McNaughton-Collins M, Walker-Corkery E, Elliott DB, and, Barry MJ,. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 2002; 95: 287-295.
13. Smith DP, King MT, Egger S, et al,. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ: British Medical Journal 2009; 340: 1-12.
14. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS,. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med 2006; 166: 465-471.
15. Soyupek F, Soyupek S, Perk H, Ozorak A,. Androgen deprivation therapy for prostate cancer: effects on hand function. Urol Oncol 2008; 26: 141-146.
16. Rosenblatt DE, Mellow A,. Depression during hormonal treatment of prostate cancer. J Am Board Fam Pract 1995; 8: 317-320.
17. Pirl WF, Siegel GI, Goode MJ, Smith MR,. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psycho-Oncology 2002; 11: 518-523.
18. Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN,. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 2004; 29: 1071-1081.
19. Cherrier MM, Aubin S, Higano C,. Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psycho-Oncology 2009; 18: 237-247.
20. Dacal K, Sereika SM, Greenspan SL,. Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc 2006; 54: 85-90.
21. Herr HW, O'Sullivan M,. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000; 163: 1743-1746.
22. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM,. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol 29: 726-32.
23. Conn VS, Hafdahl, AR, Porock DC, McDaniel R, Nielsen PJ,. A meta-analysis of exercise interventions among people treated for cancer. Support Care Cancer 2006; 14: 699-712.
24. Segal RJ, Reid RD, Courneya KS, et al,. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003; 21: 1653-1659.
25. Galvao DA, Nosaka K, Taaffe, DR, et al,. Endocrine and immune responses to resistance training in prostate cancer patients. Prostate Cancer Prostatic Dis 2008; 11: 160-165.
26. Galvao DA, Nosaka K, Taaffe DR, et al,. Resistance training and reduction of treatment side effects in prostate cancer patients. Medicine & Science in Sports & Exercise 2006; 38: 2045-2052.
27. Galvao DA, Spry NA, Taaffe DR, et al,. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 2008; 102: 44-47.
28. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU,. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 2009; 28: 340-347.
29. Culos-Reed SN, Robinson JL, Lau H, O'Connor K, Keats MR,. Benefits of a physical activity intervention for men with prostate cancer. J Sport Exerc Psychol 2007; 29: 118-127.
30. Windsor PM, Nicol KF, Potter J,. A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. Cancer 2004; 101: 550-557.
31. Carmack Taylor CL, Demoor C, Smith MA, et al,. Active for life after cancer: a randomized trial examining a lifestyle physical activity program for prostate cancer patients. Psycho-Oncology 2006; 15: 847-862.
32. Culos-Reed SN, Robinson JW, Lau H, et al,. Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention. Support Care Cancer 2010; 18: 591-599.
33. Haskell WL, Lee IM, Pate RR, et al,. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc 2007; 39: 1423-1434.
34. Department of Health and Ageing. National Physical Activity Guidelines for Adults. 2005 24/10/2012; Available from: http://www.health.gov.au/internet/ main/publishing.nsf/content/phd-physical-activity-adults-pdf-cnt.htm
35. Keogh JWL, Shepherd D, Krageloh CU, et al,. Predictors of physical activity and quality of life in New Zealand prostate cancer survivors undergoing androgen-deprivation therapy. N Z Med J 2010; 123: 20-29.
36. Stevinson C, Steed H, Faught W, et al,. Physical activity in ovarian cancer survivors: associations with fatigue, sleep, and psychosocial functioning. Int J Gynecol Cancer 2009; 19: 73-78.
37. Vallance JKH, Courneya KS, Jones, LW, Reiman T,. Differences in quality of life between non-Hodgkin's lymphoma survivors meeting and not meeting public health exercise guidelines. Psycho-Oncology 2005; 14: 979-991.
38. Lynch BM, Cerin E, Owen N, Aitken JF,. Associations of leisure-time physical activity with quality of life in a large, population-based sample of colorectal cancer survivors. Cancer Causes Control 2007; 18: 735-742.
39. Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS,. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst 2009; 101: 888-892.
40. Snaith RP, Zigmond AS,. The Hospital Anxiety and Depression Scale with the Irritability-Depression-Anxiety Scale and the Leeds Situational Anxiety Scale Manual. Nfer-Nelson: Windsor, 1994.
41. Herrmann C,. International experiences with the Hospital Anxiety and Depression Scale-a review of validation data and clinical results. J Psychosom Res 1997; 42: 17-41.
42. Nelson CJ, Mulhall, JP, Roth AJ,. The association between erectile dysfunction and depressive symptoms in men treated for prostate cancer. J Sex Med 2011; 8: 560-566.
43. Mehnert A, Lehmann C, Graefen M, Huland H, Koch, U,. Depression, anxiety, post-traumatic stress disorder and health-related quality of life and its association with social support in ambulatory prostate cancer patients. Eur J Cancer Care 2010; 19: 736-745.
44. Hagstromer M, Oja P, Sjostrom M, The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. Public Health Nutr 9: 755-62.
45. Tomioka K, Iwamoto J, Saeki K, Okamoto N,. Reliability and validity of the International Physical Activity Questionnaire (IPAQ) in elderly adults: the Fujiwara-kyo Study. J Epidemiol 2011; 21: 459-465.
46. Craig CL, Marshall AL, Sjostrom M, et al,. International physical activity questionnaire: 12-country reliability and validity. Medicine & Science in Sports & Exercise 2003; 35: 1381-1395.
47. Merom D, Phongsavan P, Chey T, Bauman A, and Australian Bureau of Statistics,. Long-term changes in leisure time walking, moderate and vigorous exercise: were they influenced by the national physical activity guidelines? J Sci Med Sport 2006; 9: 199-208.
48. Tremblay MS, Warburton DER, Janssen I, Paterson DH, Latimer AE, Rhodes RE, Kho ME, Hicks A, Leblanc AG, Zehr L, Murumets K, Duggan M, New Canadian physical activity guidelines. Applied Physiology, Nutrition, & Metabolism = Physiologie Appliquee, Nutrition et Metabolisme 2011; 36: 36-46; 47-58.
49. Armstrong T, Bauman A, Davies J, Physical Activity Patterns of Australian Adults: Results of the 1999 National Physical Activity Survey. Australian Institute of Health and Welfare: Canberra, 2000.
50. United States Department of Health and Human Services. Appendix 1. Translating Scientific Evidence about Total Amount and Intensity of Physical Activity into Guidelines. 2008 [cited 2012 4/9/2012]; Available from: http://www.health.gov/paguidelines/guidelines/appendix1.aspx.
51. Cella D, Nichol MB, Eton D, Nelson JB, Mulani P,. Estimating Clinically meaningful changes for the Functional Assessment of Cancer Therapy-Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health 2009; 12: 124-129.
52. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ,. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997; 50: 920-928.
53. Alibhai SMH, Gogov S, Allibhai Z,. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 2006; 60: 201-215.
54. Lubeck DP, Grossfeld GD, Carroll PR,. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology 2001; 58: 94-100.
55. Green HJ, Pakenham KI, Headley BC, and, Gardiner RA,. Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring. Psycho-Oncology 2002; 11: 401-414.
56. van Andel G, Kurth KH,. The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol 2003; 44: 209-214.
57. Basaria S, Lieb J, 2nd, Tang AM, et al,. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol 2002; 56: 779-786.
58. Sprangers MA, Schwartz CE,. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med 1999; 48: 1507-1515.
59. Bolmsjo I,. Existential issues in palliative care-interviews with cancer patients. J Palliat Care 2000; 16: 20-24.
60. Brooker JE, Fletcher JM, Dally MJ, et al,. Factors associated with anxiety and depression in the management of acoustic neuroma patients. J Clin Neurosci 2012; 19: 246-251.
61. Dunn AL, Trivedi MH, O'Neal HA,. Physical activity dose-response effects on outcomes of depression and anxiety. Medicine & Science in Sports & Exercise 2001; 33: S587-97; discussion 609-10.
62. Ganz PA, Hirji K, Sim MS, Schag CA, Fred C, Polinsky ML,. Predicting psychosocial risk in patients with breast cancer. Medical Care 1993; 31: 419-431.
63. Schag CA, Ganz PA, Polinsky ML, Fred C, Hirji, K, Petersen L,. Characteristics of women at risk for psychosocial distress in the year after breast cancer. J Clin Oncol 1993; 11: 783-793.
64. Maunsell E, Brisson J, Deschenes L,. Psychological distress after initial treatment of breast cancer. Assessment of potential risk factors. Cancer 1992; 70: 120-125.
65. Kissane DW, Grabsch B, Love A, Clarke DM, Bloch S, Smith GC,. Psychiatric disorder in women with early stage and advanced breast cancer: a comparative analysis. Aust N Z J Psychiatry 2004; 38: 320-326.
66. NBC Centre, NCC Initiative,. Clinical Practice Guidelines for the Psychosocial Care of Adults with Cancer. National Breast Cancer Centre: Camperdown, NSW, 2003.
67. Prince S, Adamo K, Hamel M, Hardt J, Gorber S, Tremblay M,. A comparison of direct versus self-report measures for assessing physical activity in adults: a systematic review. Int J Behav Nutr Phys Act 2008; 5: 1-24.
68. Rzewnicki R, Vanden Auweele Y, De Bourdeaudhuij I,. Addressing overreporting on the International Physical Activity Questionnaire (IPAQ) telephone survey with a population sample. Public Health Nutr 2003; 6: 299-305.
69. Grimm EK, Swartz AM, Hart T, Miller NE, Strath SJ,. Comparison of the IPAQ-Short Form and accelerometry predictions of physical activity in older adults. J Aging Phys Act 2012; 20: 64-79.
70. Schmitz KH, Courneya KS, Matthews C, et al,. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Medicine & Science in Sports & Exercise 2010; 42: 1409-1426.